Biotechnologie Dänemark

Alk-Abello AS Aktie

Aktie
WKN:  A3DHX9 ISIN:  DK0061802139 US-Symbol:  AKBLF
22,18 €
+0,00 €
0,00%
16.05.25
Depot/Watchlist
Aktienanzahl *
202,57 Mio.
Marktkapitalisierung *
4,52 Mrd. €
Streubesitz
37,38%
KGV
41,22
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 17.09.2024
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,57: MK4YXF
Werbung

Alk-Abello AS News

28.02.25 - PR Newswire
U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy
U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite ...
05.02.24 - GlobeNewswire
ALK’s 2030 CO2 reduction targets have been approved by SBTi
ALK’s near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based Targets initiative.
04.01.24 - PR Newswire
ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy
ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy PR Newswire
25.01.23 - PR Newswire
U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents
U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents PR Newswire
11.08.22 - PLX
ALK-Abello Q2 EBITDA DKK 107 Million vs. Estimate DKK 80 Million
(PLX AI) – ALK-​Abello Q2 revenue DKK 1,045 million vs. estimate DKK 970 million.
27.06.22 - PLX
ALK-Abello Starts Phase 1 Trial of SLIT Tablet in Peanut Allergy
(PLX AI) – ALK-​Abello begins clinical trial of its SLIT-​tablet for the treatment of peanut allergy. • ALK-​Abello Phase I clinical trial of its novel investigational sublingual allergy ...
12.05.22 - PLX
ALK-Abello Q1 EBITDA DKK 272 Million vs. Estimate DKK 240 Million
(PLX AI) – ALK-​Abello Q1 revenue DKK 1,155 million vs. estimate DKK 1,130 million. • Outlook FY revenue growth 8-12%
23.03.22 - wallstreetONLINE Redaktion
Rendite trotz Stagnation: Wall Street: Diese 30 Aktien rocken die Stagflation
Die Wall Street glaubt, dass die Weltwirtschaft vor einer Stagflation steht. Für einige ist dieses toxische Duo aus Inflation und stagnierender Wirtschaft bereits am Start. Bestimmte ...
03.03.22 - PLX
ALK-Abello Says China Waives Phase 3 Trial for Dust Mite Allergy Tablet
(PLX AI) – ALK-​Abello Clinical trial waiver in China opens door to 2022 registration filing for ALK’s dust mite allergy tablet. • ALK-​Abello can submit BLA in China without finalising the ...
08.02.22 - PLX
ALK-Abello Q4 EBITDA DKK 136 Million vs. Estimate DKK 128 Million
(PLX AI) – ALK-​Abello Q4 revenue DKK 1,099 million vs. estimate DKK 1,064 million. • Outlook FY revenue growth 8-12%
01.12.21 - PR Newswire
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma
The Lancet Regional Health - Europe publishes 'real-​world evidence' from ALK-​sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and ...
01.12.21 - PR Newswire
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma
The Lancet Regional Health - Europe publishes 'real-​world evidence' from ALK-​sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and ...
25.11.21 - PLX
ALK-Abello Board Member Søren Niegel Sells Shares for DKK 20 Million
(PLX AI) – ALK-​Abello Board Member Søren Niegel sells shares for DKK 20 million. • Niegel sold 6,514 shares
11.11.21 - PLX
ALK-Abello Raises Outlook After Q3 Earnings Much Better Than Expected
(PLX AI) – ALK-​Abello raises full-year outlook after third-​quarter earnings were much better than expected. • EBITDA rose 114% largely on the strong sales growth and improved gross ...
11.11.21 - PLX
ALK-Abello Q3 Revenue DKK 928 Million vs. Estimate DKK 882 Million
(PLX AI) – ALK-​Abello outlook FY revenue growth 11-12%.
16.08.21 - PLX
ALK-Abello Board Member Lindmark Buys Shares for About DKK 600,000
(PLX AI) – ALK-​Abello board member Bertil Lindmark buys 201 shares at DKK 2,962 per share.
11.08.21 - PLX
ALK-Abello Q2 Revenue DKK 868 Million vs. Estimate DKK 872 Million
(PLX AI) – ALK-​Abello outlook FY revenue growth 10-12%. • Outlook FY EBITDA DKK 450-500 million
09.08.21 - PLX
ALK-Abello Outlook FY Revenue Growth 10-12%
(PLX AI) – ALK-​Abello outlook FY EBITDA DKK 450-500 million.
30.07.21 - PLX
ALK-Abello, Grandpharma Partner for Adrenaline Autoinjector in China
(PLX AI) – ALK-​Abello ALK and Grandpharma team up to market the first adrenaline autoinjector in China. • ALK-​Abello says agreement to accelerate ALK's long-term growth and ...
03.06.21 - PR Newswire
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - Acquisition Supports ALK's Commitment to Provide ...

Newssuche

Videos

newspaper
14.05.25 +1,01%
Technical Trading: Die 3 besten Monate...
10yr T-Notes Long Typ: Turbo Open End WKN: NG8ZZF Hebel: 14,89 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
OSZAR »